罗格列酮对糖尿病大鼠肾脏保护作用机制的探讨

目的 探讨罗格列酮对糖尿病大鼠肾脏的保护作用机制。方法 将大鼠分为正常组、糖尿病组、小剂量罗格列酮组、大剂量罗格列酮组。药物干预4周后，检测各组大鼠的血糖（BS）、三酰甘油（TG）、胆固醇（TC）、肌酐（Scr）水平及尿白蛋白定量（24h）。随后处死大鼠，测定肾组织中丙二醛（MDA）含量、总抗氧化能力（T-AOC）及铜锌超氧化物歧化酶（Cu-ZnSOD）、谷胱甘肽过氧化酶（GSH-Px）、核转录因子-κB（NF-κB）的活性。同时留取。肾脏组织作PAS染色行病理检查。RT-PCR和免疫组化法检测。肾组织中单核细胞化学吸引蛋白质1（MCP-1）mRNA及蛋白质的表达。结果 与糖尿病组相比，大剂量罗格列酮干预组BS、TC、TG差异无统计学意义；而。肾组织MDA含量、MCP-1mRNA及蛋白质表达、NF-κB活性差异有统计学意义（P〈0．05），SOD、GSH-Px、T-AOC活性显著上升；肾小球面积及体积减小。结论大剂量的罗格列酮可显著改善糖尿病大鼠的。肾脏损害，其机制可能与其抗氧化，抑制NF-κB活性，降低MCP-1的含量有关。     

Expression of cell cycle regulators in squamous cell carcinoma of maxillary sinus and their significance]

OBJECTIVE: To investigate the clinicopathlogical significance of cyclinE, cyclinD1, P21WAF1/CIP1 and P27KIP1 expression in squamous cell carcinoma of maxillary sinus. METHODS: The expression of cyclinE, cyclinD1, P21WAF1/CIP1 and P27KIP1 was examined by the method of immunohistochemistry in inflammatory mucosa of maxillary sinus(10), inverting papilloma of maxillary sinus(20) and squamous cell carcinoma of maxillary sinus (50). RESULTS: (1) In inflammatory mucosa, inverting papilloma and squamous cell carcinoma, the positive immunostaining rates of cyclinD1 protein were 10.0%, 25.0%, 48.0% respectively (P < 0.05); cyclinE protein was 20.0%, 35.0%, 58.0% respectively (P < 0.05); P21WAF1/CIP1 protein was 80.0%, 65.0%, 40.0% respectively (P < 0.05) and P27KIP1 protein was 70.0%, 75.0%, 40.0% respectively (P < 0.05). (2) There was no significance between the clinical type, T stage and clinical stage of carcinoma of maxillary sinus and the expression of cyclinD1, cyclinE, P21WAF1/CIP1 and P27KIP1 (P > 0.05). (3) P21WAF1/CIP1 positive expression in highly, moderately and poorly differtiated carcinomas were 73.2% (11/15), 58.9% (11/19), 25.0% (4/16) respectively (P < 0.05). CONCLUSION: (1) With the development of the lesion, the positive immunostaining rate of cyclinE and cyclinD1 protein increases, while the rate of P21WAF1/CIP1 and P27KIP1 protein decreases. (2) P21WAF1/CIP1 expression is associated with tumour cell differentiation. (3) The mutual mechenism of cell cycle regulators plays an important role in the squamous cell carcinoma of maxillary sinus. The quantity and the frequency of four kinds of gene expression increase with the progression of maxillary sinus carcinogenesis.     

SPECT探头系统的校正与调试

本文阐明了对SPECT探头校正与调试的重要性,特别是对探头校正与调试的具体方法与步骤作了详细介绍.     

蛋白酶对降低异常精液粘稠度的实验对比研究

目的通过不同蛋白酶类对降低高粘稠度精液的粘稠度效果对比,寻找理想的降低精液粘稠度的药物。方法将高粘稠度精液标本分为两组,A组:31例采用α-糜蛋白酶降低精液粘稠度:B组:32例采用尿激酶降低精液粘稠度;两组均观察用药前后的精子活动力。采用配对t检验和单因素方差分析对所得数据作统计学处理。结果高粘稠度精液用药物(α-糜蛋白酶或者尿激酶)液化精液后,精子的活动力较用药前有明显提高(P<0．001);用药前后精液的粘稠度都存在着明显的差异,精液的粘稠度分别下降44．83％和55．45％(P<0．001);在A组和B组的对比研究中,单因素方差分析检验提示:用药后两组间粘稠度数据有显著的差异(P<0．001￡(?)。结论蛋白酶可以有效地降低异常精液粘稠度的精液,从实验结果提示尿激酶降低精液粘稠度的效果优于α-糜蛋白酶,这有助于临床开展应用性研究和治疗。     

深静脉血栓形成患者凝血因子ⅩⅢ Val34Leu基因多态性检测

目的:探讨凝血因子ⅩⅢ(FⅩⅢ)Val34Leu基因多态性与中国人群深静脉血栓形成(DVT)发病的相关性.方法:利用聚合酶链反应和限制性片段长度多态性(PCR-RFLP)方法,检测了103例DVT患者与106例正常对照的FⅩⅢVal34Leu基因多态,并加以对照分析.结果:103例DVT患者FⅩⅢVa134Leu基因型均为野生型V/V,未见突变类型;106例对照组中发现1例突变杂合子V/L.2组基因型频率、等位基因频率相互比较,差异均无统计学意义(P＞0.05).结论:FⅩⅢVal34Leu对中国人群DVT有保护作用的可能性极小.     

炎症性肠病危险因素的流行病学调查研究

目的通过病例调查，筛选IBD的危险因素。方法采用问卷方式，对72例确诊IBD患者及72例配对的健康个体调查，对结果进行COX回归分析，筛选出IBD的致病危险因素。结果COX回归分析提示紧张度、牛奶和油炸食品在IBD致病因素中具有统计学意义。结论紧张度、牛奶和油炸食品可能是IBD的致病危险因素。     

血清瘦素在男生青春发育期的动态观察

目的 探讨血清瘦素在男生青春期发育中的作用。方法 健康男生170名，调查首次遗精时间，测定血清瘦素、睾酮、促卵泡成熟激素、黄体生成激素水平，采用多元Logistic回归模型分析男生青春期发育的影响因素；同时，连续两年观察，分析血清瘦素在青春期的动态变化。结果 末次研究已遗精组血清瘦素、睾酮、促卵泡成熟激素、黄体生成激素水平均明显高于未遗精组。多因素分析显示血清瘦素、睾酮、促卵泡成熟激素、体重为男生青春期发育的独立影响因素。初次资料分析，遗精前组血清瘦素、睾酮明显高于未遗精组。结论 血清瘦素、睾酮、促卵泡成熟激素、体重为男生青春期发育的独立影响因素，男生遗精前期血清瘦素、睾酮已有明显改变。     

黄芪注射液对儿童肾病综合征尿蛋白与血浆蛋白的影响

目的 :观察黄芪注射液对儿童肾病综合征尿蛋白与血浆蛋白的影响。方法 :将我科 1996年 10月～2 0 0 2年 10月收治的小儿肾病综合征 30例 ,随机分为 2组。治疗组 17例 ,采用强的松加黄芪注射液治疗 ;对照组 13例仅给强的松治疗。结果 :治疗 1个月后 ,治疗组临床症状及血液生化指标等明显优于对照组 ,2 4h尿蛋白降低与血浆白蛋白升高与对照组比较 ,差异有统计学意义 (P <0 .0 1)。结论 :黄芪注射液对儿童肾病综合征有明显疗效 ,尤其在减轻蛋白尿 ,提高血浆蛋白方面 ,值得临床应用     

Association of the expressions of platelet-derived growth factor receptor and c-Fos with the biological characteristics of bladder cancer.

OBJECTIVE: To elucidate the relation of platelet-derived growth factor receptor (PDGFR) and c-Fos protein expressions with human bladder transitional epithelial cell carcinoma (BTCC). METHODS: The expressions of PDGFR and c-Fos were investigated in 11 normal bladder tissue samples, 14 adjacent non-carcinoma tissues and 43 BTCC tissues by means of SP immunohistochemical technique. RESULTS: The c-Fos expression was found in the cell nuclei and cytoplasm, and PDGFR in the nuclear membrane, cytoplasm, and cellular membrane. PDGFR and c-Fos were detected in 81.40% and 48.83% of the BTCC tissues respectively, at the rates both significantly higher than those in normal and adjacent non-carcinoma tissues (P<0.05). Correlation between the expression of c-Fos and the tumor grading was noted (P<0.05). The expressions of PDGFR and c-Fos in tumor blood vessels were significantly higher than those in normal vessels. CONCLUSIONS: The expressions of PDGFR and c-Fos might be involved in the development of BTCC, possibly related to the angiogenesis of the tumors. c-Fos expression can indicated the cell proliferative status of the BTCC.     

人端粒酶逆转录酶在肿瘤免疫治疗中的应用

寻找有效的抗原表位是近期肿瘤免疫治疗的热点．人端粒酶逆转录酶(hTERT)的免疫学特性使其成为肿瘤免疫治疗中一个吸引人的目标。从人和鼠系统获得的数据证实，细胞毒淋巴细胞(CTL)能识别hTERT特异的肽并杀死多种组织类型hTERT表达的肿瘤细胞。由于hTERT在人肿瘤组织中的广泛表达，在极少正常组织的低水平表达，临床试验已开始检验将hTERT作为肿瘤免疫治疗目标的可行程度。近期树突状细胞(DC)转运系统及其相关技术的发展和成熟提供了一个快速有效筛选抗原肽的方法。